Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 14/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | BLK | P51451 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3451467 | 0.93 | JAK1 (0.39) | BRAFJAK1BLKJAK3ABL1 | |
| SCHEMBL3449308 | 0.90 | CSNK2A1 (0.36) | BRAFCSNK2A1JAK1BLKJAK3 | |
| SCHEMBL3451426 | 0.90 | JAK1 (0.36) | BRAFCSNK2A1JAK1BLKJAK3 | |
| SCHEMBL3450030 | 0.90 | ABL1 (0.38) | CSNK2A1L3MBTL1ABL1BCR | |
| SCHEMBL13312538 | 0.90 | ACVR1B (0.37) | BRAFJAK1BLKJAK3 | |
| SCHEMBL3449228 | 0.89 | SYK (0.36) | JAK1BLKJAK3ABL1BCR | |
| SCHEMBL3450351 | 0.89 | MAPK10 (0.45) | BRAFRAF1 | |
| SCHEMBL3450175 | 0.88 | ABL1 (0.36) | CSNK2A1ABL1BCR | |
| SCHEMBL3448975 | 0.88 | CSNK2A1 (0.39) | CSNK2A1 | |
| SCHEMBL3449838 | 0.88 | RAF1 (0.44) | CSNK2A1RAF1AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | BRAF 1251/4885CSNK2A1 1858/4885RAF1 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.